American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects.
By J. Carver, C. Shapiro, Andrea Ng, L. Jacobs, C. Schwartz, Katherine S. Virgo, K. Hagerty, M. Somerfield, D. Vaughn. Journal of Clinical Oncology, 2007
777 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/56398c9f825719847e8ebb6bb241ce6d32538a8d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy (2015, neutral): “001 Breast cancer 131 (58) 1213 (51) Hodgkin’s disease 10 (4) 113 (5) Non-Hodgkin’s lymphoma 46 (20) 695 (29) Myeloma 8 (4) 144 (6) Ovarian 2 (1) 67 (3) Other hematoncologic diseases 10 (4) 76 (3) Other solid tumors 19 (8) 91 (4) Cumulative anthracycline dose, ‡§ mg/mq 359 172 299 144 <0.”
- Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer (2010, neutral): “Although many studies of the cardiac toxicity of breast cancer have focused on ischemic disease, the detrimental effects of radiation on other cardiac structures such as the peri-cardium, myocardium, valves, conduction system, and autonomic system have also been described (Table 4) (8).”
- Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management (2016, background): “impact of these changes on cardiac function are unknown; thus, further research is needed.(136) In summary, a novel approach based on the use of cardiac”
- Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. (2014, neutral): “Pediatric, ALL, lymphoma, solid tumour, or AML 56 (median 12·7 [4-28]), 61%, 32 controls Doxorubicin, daunorubicin, or idarubicin.”
- Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. (2014, background): “However, valvular heart disease may manifest in oncologic patients for a number of reasons, including preexisting valve lesions, 55-57 concomitant radiation therapy, 58 severe infection as a complication of chemotherapy, or CTRCD. Primary or secondary cardiac tumors may rarely affect valve function ”
- Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. (2014, neutral): “Although monitoring guidelines have been proposed for several potentially cardiotoxic treatments, limited data are available to formulate evidencebased screening and follow-up recommendations for CTRCD.(41) Although LVEF is a robust predictor of cardiac outcomes in the general population, it has low”